Drugs / IVX037
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05427487 | Feb 2023 → Jun 2028 expected | colorectal cancer, gastric cancer, ovarian cancer | ImmVirx Pty Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-04-21 | ImmVirx Pty Ltd | Results ImmVirX Reports Encouraging Phase 1b Clinical Data for IVX037 and Highlights Broad Preclinical Activity of IVX055 at AACR 2026 immvirx.com ↗
IVX037 data demonstrate favourable safety profile, abscopal effects and enhanced activity in KRAS/BRAF-mutant tumours; IVX055 shows potent anti-tumour activity across multiple solid tumour types |
| 2025-10-20 | ImmVirx Pty Ltd | Results ImmVirX Presents Promising Clinical Data on IVX037 at ESMO 2025, Highlighting Activity in MSS-CRC and Ovarian Cancer immvirx.com ↗
Intratumoural IVX037 showed encouraging biological and clinical activity in microsatellite stable colorectal cancer (MSS-CRC), both as a monotherapy and in combination with the PD-1 inhibitor sintilimab, particularly in KRAS/BRAF-mutant tumours. |
| 2025-04-29 | ImmVirx Pty Ltd | Results ImmVirX presents clinical and preclinical updates at American Association for Cancer Research (AACR) Annual Meeting immvirx.com ↗
Confirmed pathologic complete response in a target lesion in a colorectal cancer patient with no new sites of metastatic lesions approaching two years since commencing treatment |
| 2025-03-27 | ImmVirx Pty Ltd | Results ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, Chicago immvirx.com ↗
New preclinical data on lead asset IVX037 and second asset IVX055, both bioselected oncolytic RNA immunotherapies, will be presented in a poster outlining their potent anti-tumour activity across a range of tumour types. |
| 2024-08-16 | ImmVirx Pty Ltd | Results ImmVirX presents update on Phase 1a/b Clinical Study at Medical Oncology Group of Australia Annual Meeting immvirx.com ↗
Signs of anti-cancer monotherapy activity in 2 of first 10 late-stage colorectal cancer patients evaluable for response. |
| 2023-11-06 | ImmVirx Pty Ltd | Results ImmVirX presents on its Phase 1a Clinical Study at Society for Immunotherapy of Cancer (SITC) Annual Meeting immvirx.com ↗
To date IVX037 intralesional administration has been generally well tolerated with no dose-limiting toxicities observed. |
All press releases naming this drug 10 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVX037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05427487 ↗ |
| Modality | Other / unclassified | “Bioselected oncolytic RNA virus” NCT05427487 ↗ |
| Route | Other | “IVX037 administered intratumorally” NCT05427487 ↗ |